Jechobio JL15003 Secures Dual Recognition with Oral Presentations at Leading CSCO and SNO Oncology Conferences

Recently, research findings on JL15003 Injection — a Class 1 innovative drug independently developed by Jechobio for recurrent glioblastoma (rGBM) — have been accepted for oral presentation at two prestigious domestic and international oncology conferences, highlighting the strength of China’s homegrown innovative drug R&D. Recurrent glioblastoma is characterized by limited treatment options and poor prognosis, representing a major unmet clinical need. As an innovative therapy dedicated to this indication, JL15003 presents systematic key safety and efficacy data from its studies, opening a new exploratory direction for rGBM management. Domestic Showcase: Oral Presentation at the CSCO Annual Meeting Innovation Session As a flagship event in China’s oncology community, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan from September 10 to 14. Selected from a large pool of submissions, the JL15003 study was featured in the innovation track with an oral presentation on the afternoon of September 11. Its robust data and clinical value garnered extensive attention and high recognition from attending experts. Global Spotlight: Featured Oral Presentation at the SNO Annual Meeting Alongside its domestic milestone, JL15003 has earned further acclaim on the global stage. The Annual Meeting of the Society for Neuro-Oncology (SNO) — the world’s premier neuro-oncology conference, to be hosted in Hawaii from November 19 to 23 — has granted JL15003 an oral presentation slot. The corresponding study abstract will be published in the journal , marking professional validation of the research’s merit by international peers. The acceptance of JL15003 for oral presentation at both CSCO and SNO, two authoritative conferences in the field, reflects the strong academic regard the study has received across domestic and global communities. This dual breakthrough not only validates the scientific value of JL15003, but also underscores Jechobio’s leading position in oncolytic virus therapy development for recurrent glioblastoma. These selections will build a high-level academic exchange platform for JL15003, accelerate its clinical translation, and bring new treatment hope to patients with recurrent glioblastoma. Moving forward, Jechobio will remain guided by clinical needs, continue to advance original innovation, and contribute China’s expertise to the global fight against cancer.

The release as fetched from its publisher. jechobio.com ↗